Takeda buys coeliac drug licence from COUR Pharmaceuticals

Takeda has bought a licence for a coeliac disease drug from COUR Pharmaceuticals, after the US biotech announced supportive phase 2a trial data.

Debt-laden Takeda to sell OTC drugs in Middle East and Afric...

Takeda is to sell off a portfolio of over-the-counter and prescription drugs in the Near East, Middle East, and Africa for $200 million to Acino, as the Japanese company aims to pay off bil

ImaginAb joins with AZ, Pfizer and Takeda to develop tumour ...

LA-based biotech ImaginAb has signed a multi-party agreement with pharma giants AstraZeneca, Pfizer, and Takeda, for technology that allows scientists to see inside tumours, and monitor whe

Takeda breaks into top 20 largest pharmas with Shire merger

Takeda broke into the list of top 20 publicly traded innovative pharma companies after its $62 billion merger with Shire earlier this year, according to a new analysis using market capitali

Takeda eyes emerging markets asset sale to trim its debt; re...

Evotec announces potential $850m R&D partnership with Takeda

Germany’s Evotec has announced another high-profile R&D partnership with big pharma, beginning a multi-year R&D partnership with Takeda, focusing on discovering small molecule drugs